# US 2013/0156696 A1 · Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156696 A1
- Document ID: US20130156696A1
- Status: Published application
- Kind: A1
- Application number: 13/118,074
- Filed: 2011-05-27
- Published: 2013-06-20
- Earliest claimed: 2000-09-07
- Assignees: Case Western Reserve University
- Inventors: John R. SCHREIBER; Kulwant KAUR
- Web page: https://patentgrep.com/patent/US20130156696A1

## CPC

- A61K 39/40: bacterial
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/1214: Pseudomonadaceae (F)
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- A01K 2207/15: Humanized animals
- A01K 2217/00: Genetically modified animals
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2227/105: Murine
- A01K 2267/01: Animal expressing industrially exogenous proteins
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention described herein provides for human antibodies produced in non-human animals that specifically bind to Pseudomonas aeruginosa Lipopolysaccharide (LPS). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.

## Claims

### Claim 1

An isolated human monoclonal antibody or antigen-binding portion thereof wherein the antibody specifically binds the lipopolysaccharide (LPS) O-specific side chain of Pseudomonas aeruginosa of serotype 06ad.

### Claim 2 (depends on 1)

The isolated human monoclonal antibody or antigen-binding portion thereof according to claim 1, wherein the antibody or portion thereof has one or more properties selected from the group consisting of:
a) opsonizes Pseudomonas aeruginosa of serotype 06ad;
b) promotes complement-dependent phagocytosis of Pseudomonas aeruginosa of serotype 06ad;
c) enhances the immune response to Pseudomonas aeruginosa of serotype 06ad; and
d) mediates the killing of Pseudomonas aeruginosa of serotype 06ad.

### Claim 3 (depends on 2)

The isolated human antibody or antigen-binding portion thereof according to claim 2, wherein said mediating of the killing of said Pseudomonas aeruginosa comprises delivery of an agent lethal to said Pseudomonas aeruginosa.

### Claim 4 (depends on 2)

The isolated human antibody or antigen-binding portion thereof according to claim 2, wherein said mediating of the killing of said Pseudomonas aeruginosa comprises enhancing the immune response to said Pseudomonas aeruginosa.

### Claim 5 (depends on 1)

The isolated human antibody or antigen-binding portion thereof according to claim 1, wherein said antibody or antigen-binding portion thereof inhibits, treats, or prevents infection with Pseudomonas aeruginosa of serotype 06ad.

### Claim 6 (depends on 1)

The isolated human antibody or antigen-binding portion thereof according to claim 1, wherein said antibody or portion thereof comprises:
a) a kappa light chain, wherein said kappa light chain comprises the amino acid sequence of SEQ ID NO: 4;
b) a heavy chain, wherein said heavy chain comprises the amino acid sequence of SEQ ID NO: 2; or
c) both a) and b).

### Claim 7 (depends on 1)

The isolated human antibody or antigen-binding portion thereof according to claim 1, wherein said antibody or portion thereof comprises:
a) a kappa light chain, wherein said kappa light chain is encoded by a nucleic acid comprising SEQ ID NO: 3;
b) a heavy chain, wherein said heavy chain is encoded by a nucleic acid comprising SEQ ID NO: 1; or
c) both a) and b).

### Claim 8 (depends on 1)

A kit comprising the antibody or antigen-binding portion thereof according to claim 1, a pharmaceutically acceptable carrier, and a container.

### Claim 9 (depends on 8)

The kit according to claim 8, further comprising instructions for use.

### Claim 10 (depends on 1)

A method for treating or preventing infection with Pseudomonas aeruginosa of serotype 06ad, comprising the step of administering an isolated human antibody according to claim 1 to a patient at risk of being infected with, or currently infected with, Pseudomonas aeruginosa of serotype 06ad.

### Claim 11 (depends on 10)

The method according to claim 10, further comprising the step of administering one or more of the following: toxins, complement proteins, radiolabeled proteins, cytokines, antibiotics, or any combination thereof.

### Claim 12 (depends on 1)

A method for making the isolated human antibody or antigen-binding portion thereof of claim 1, comprising: a) immunizing a non-human animal having incorporated a human immunoglobulin locus therein with the lipopolysaccharide (LPS) O-specific side chain of Pseudomonas aeruginosa of serotype 06ad; b) allowing said non-human animal to mount a humoral response to said antigenic composition; and c) isolating said human antibody from said non-human animal.

### Claim 13 (depends on 1)

The isolated human antibody or antigen-binding portion thereof according to claim 1, wherein the antibody or portion thereof is produced by a process comprising the steps of:
a) immunizing a non-human animal comprising a human immunoglobulin locus with an antigen selected from the group consisting of an isolated Pseudomonas aeruginosa LPS preparation, a virile Pseudomonas aeruginosa cell preparation, an attenuated Pseudomonas aeruginosa cell preparation, and a killed Pseudomonas aeruginosa cell preparation;
b) allowing said non-human animal to mount an immune response to said antigen; and
c) isolating said antibody from said non-human animal;
wherein the Pseudomonas aeruginosa is Pseudomonas aeruginosa of serotype 06ad.

### Claim 14 (depends on 1)

The isolated human antibody or antigen-binding portion thereof according to claim 1, wherein said antibody or portion thereof is isolated from a non-human animal or cell and is free of contaminating human biomaterials.

### Claim 15

A human monoclonal antibody or an antigen-binding portion thereof that inhibits the binding of an antibody produced by a hybridoma cell line having ATCC Accession Number PTA-4073 to an O-specific side chain of Pseudomonas aeruginosa of serotype 06ad.

### Claim 16 (depends on 1)

An antibody or antigen-binding portion thereof according to claim 1, wherein said antibody or portion thereof comprises:
a) a heavy chain, wherein said heavy chain is encoded by a nucleic acid comprising the CDR1, CDR2 and CDR3 regions shown in FIG. 9;
b) a kappa light chain, wherein said kappa light chain is encoded by a nucleic acid comprising the CDR1, CDR2 and CDR3 regions shown in FIG. 10; or
c) both a and b.

### Claim 17 (depends on 1)

A passive vaccine for preventing or inhibiting infection with Pseudomonas aeruginosa of serotype 06ad comprising one or more human monoclonal antibodies or an antigen-binding portion thereof according to claim 1.

### Claim 18 (depends on 1)

A method for detecting the presence of Pseudomonas aeruginosa of serotype 06ad in a biological sample comprising the steps of contacting said sample with an antibody or antigen-binding portion thereof according to claim 1.

### Claim 19

An isolated human antibody or antigen-binding portion thereof, wherein the amino acid sequence of said antibody or portion thereof is the same as the amino acid sequence of the human antibody produced by the hybridoma cell line having American Type Culture Collection Accession Number PTA-4073 or the antigen-binding portion thereof.

### Claim 20 (depends on 1)

The isolated human antibody or antigen-binding portion thereof according to claim 1, wherein said antibody or portion thereof comprises:
a) a kappa light chain, wherein said kappa light chain is encoded by a nucleic acid which encodes an amino acid sequence comprising SEQ ID NO: 4;
b) a heavy chain, wherein said heavy chain is encoded by a nucleic acid which encodes an amino acid sequence comprising SEQ ID NO: 2; or
c) both a) and b).
